Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Christian Lerchenmueller"'
Autor:
Georg Hess, Karola Wagner, Ulrich Keller, Paul La Rosee, Johannes Atta, Kai Hübel, Christian Lerchenmueller, Daniel Schoendube, Mathias Witzens-Harig, Christian Ruckes, Christoph Medler, Christina van Oordt, Wolfram Klapper, Matthias Theobald, Martin Dreyling
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e398 (2020)
Abstract. In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous
Externí odkaz:
https://doaj.org/article/df50cb3a9f414acba4d126da7585c1a9
Autor:
Ulrich Keller, Mathias Witzens-Harig, Daniel Schoendube, Christoph Medler, Paul La Rosée, Georg Hess, Karola Wagner, Martin Dreyling, Christian Ruckes, Christina van Oordt, Wolfram Klapper, Johannes Atta, Christian Lerchenmueller, Matthias Theobald, Kai Hübel
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e398 (2020)
HemaSphere
HemaSphere
In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with relapsed or refractory (r/r) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1 to 3 previous therapies
Autor:
Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, Tina Nielsen, Deniz Sahin, Wolfgang Hiddemann, Robert E Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van eygen, Randeep Sangha, Pam Mckay, Jonathan Wilson, Richard Van Der Jagt, Daryl Roitman, Marek Trneny, Jiri Mayer, Katell Le Du, Philippe Solal-Celigny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange-Krex, Axel Florschütz, Hans-Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Hess, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling-Kaiser, Martin Hoffmann, Zita Borbenyi, Miklos Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Parraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, Jose Antonio Marquez Navarro, Carlos Grande Garcia, Herman Nilsson-Ehle, Helen Mccarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin Dyer, Ruth Pettengell, John Seymour, John Gribben, Saad Al-Ismail, Faris Al-Refaie, Norbert Blesing, Christopher Macnamara, Ann O'callaghan, Andrew Haynes, George Follows, Roderick Johnson, David Cunningham, Kristian Bowles, Graham Collins, Eve Gallop-Evans, Stephen Robinson, Chezhian Subash, James Bailey, Viran Holden, Jeffrey Neidhart, Moacyr De Oliveira, Haluk Tezcan, Kevin Kim, Suman Kambhampati, Keith Lanier, John Mcclean, Kensei Tobinai, Kiyohiko Hatake, Michinori Ogura, Toshiki Uchida, Kiyoshi Ando, Tomohiro Kinoshita, Thomas Höhler, Heribert Stauder, Andreas Kirsch, Michael Koenigsmann, Stephan Kremers, Thomas Illmer, Mathias Witzens-Harig, Paul La Roseé, Jan Dürig, Michael Kneba, Manfred Hensel, Stefan Fuxius, Lothar Bergmann, Kai Hübel, Christian Buske, Reinhard Marks, Gerald Wulf, Christian Lerchenmueller, Rudolf Schmits, Mark Reinwald, Eva Lengfelder, Fiona Scott, Takaaki Chou, Masafumi Taniwaki, Isao Yoshida, Kenichi Ishizawa, Naokuni Uike, Nobuhiko Uoshima, Yuri Kamitsuji, Shinsuke Iida, Ken Ohmine, Kisato Nosaka, Kazuhiko Ide, Takayuki Ishikawa, Pierre Desjardins, Nicholas Finn, Jun Zhu, Wei Li, Li Yu, Hanyun Ren, Yuan Kai Shi, Gang Wu, Xiaonan Hong, Qingyuan Zhang, Jifeng Feng, Rong Zhan, Tongyu Lin, Sirpa Leppa, Regis Costello, Adrian Tempescul, Laurence Sanhes, Olivier Tournilhac, Heinz Kirchen, Holger Hebart, Rudolf Weide, Kathleen Jentsch-Ullrich, Irit Avivi, Arnon Nagler, Ronit Gurion, Ofer Shpilberg, Pietro Leoni, Luca Baldini, Olga Samoylova, Alexandr Myasnikov, Tran-Der Tan, Hung Chang, Kyoya Kumagai, Norifumi Tsukamoto, Kunihiro Tsukasaki, Patrick Beatty, Noriko Usui, Koji Izutsu, Tohru Murayama, Tatsuo Ichinohe, Kohmei Kubo, Fumihiro Ishida, J. Thaddeus Beck, Frank Griesinger, Dzhelil Osmanov, Shaker Dakhil, Aline Clavert, Dai Maruyama, Yasuhito Terui, Kazuhito Yamamoto, Ekkehard Eigendorff, Tsutomu Kobayashi, Satoshi Ichikawa, Ilseung Choi, Katsuya Wada, Yoshitaka Kikukawa, Masao Matsuoka, Takayuki Yoshino, Yosuke Minami
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary
Autor:
Sebastian Stintzing, L. Fischer von Weikersthal, S-E. Al-Batran, Marlies Michl, Ursula Vehling-Kaiser, Dominik Paul Modest, Christian Lerchenmueller, Tobias Heintges, Markus M. Lerch, Christoph Kahl, Alexander Kiani, Markus Scholz, Werner Scheithauer, Frank Kullmann, Sebastian Mueller, Jörg Hielscher, Thomas Decker, Volker Heinemann, T. Kirchner, G. Seipelt, Martina Stauch, Andreas Jung
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(8)
Carcinoembryonic antigen (CEA) response may be a surrogate for response and long-term outcome in (K)RAS wild-type mCRC receiving first-line targeted therapy. FOLFIRI and cetuximab induced a greater CEA response than FOLFIRI and bevacizumab. CEA respo
Autor:
Ulrich Keller, Georg Hess, Christoph Medler, Kai Huebel, Mathias Witzens-Harig, Christian Ruckes, Paul LaRosee, Johannes Atta, Wagner Karola, Christian Lerchenmueller, Martin Dreyling, Ulrich Bitz
Publikováno v:
Blood. 126:3930-3930
Abstract 2697 Background: mTOR inhibition has been shown to be effective in various subtypes of malignant lymphomas. Based on a phase III trial in relapsed MCL which proved superiority of temsirolimus to standard options, the drug is approved for thi
Autor:
Christian Lerchenmueller, Ludwig Fischer von Weikersthal, Thomas Kirchner, Carsten Hielscher, Tobias Heintges, Sebastian Stintzing, G. Seipelt, Frank Kullmann, Dominik Paul Modest, Christoph Kahl, Salah-Eddin Al-Batran, Markus Moehler, Swantje Held, Volker Heinemann, Alexander Kiani, Thomas Decker, Martina Stauch, Ursula Vehling-Kaiser, Werner Scheithauer, Andreas Jung
Publikováno v:
Journal of Clinical Oncology. 33:3589-3589
3589 Background: The FIRE-3 study (AIO KRK-0306) was designed as a randomized multicenter trial to compare the efficacy of FOLFIRI plus cetuximab (cet) to FOLFIRI plus bevacizumab (bev) as first-line treatment in KRAS WT mCRC patients. FOLFIRI plus c
Autor:
Andreas Jung, Salah-Eddin Al-Batran, Sebastian Stintzing, Christian Lerchenmueller, Christoph Kahl, Dominik Paul Modest, Tobias Heintges, Ludwig Fischer von Weikersthal, Marlies Michl, G. Seipelt, Volker Heinemann, Werner Scheithauer, Frank Kullmann, Martina Stauch, Ursula Vehling-Kaiser, Joerg Hielscher, Thomas Kirchner, Thomas Decker, Alexander Kiani, Michael Scholz
Publikováno v:
Journal of Clinical Oncology. 33:3581-3581
3581 Background: Recently, Prager et al. proposed the hypothesis that carcinoembryonic antigen (CEA) is involved in tumor angiogenesis and therefore might predict bevacizumab-based treatment response in metastatic colorectal cancer (mCRC) (Cancer Res
Autor:
Markus Moehler, A. Jagenburg, L. Fischer von Weikersthal, Alexander Kiani, S.-E. Al-Batran, Ursula Vehling-Kaiser, Christoph Kahl, Volker Heinemann, Clemens Giessen, T. Kirchner, Frank Kullmann, Thomas Decker, Sebastian Stintzing, Christian Lerchenmueller, Swantje Held, Tobias Heintges, Werner Scheithauer, G. Seipelt, Andreas Jung, Dominik Paul Modest
Publikováno v:
Annals of Oncology. 25:v1
Aim: FIRE-3 compared 1st-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type mCRC patients. An independent radiological review was carried out to evaluate tumor response according to RECIST 1.1 and to define ea
Autor:
Tamas Suto, An Vanderbroek, Faress Husseini, Christian Lerchenmueller, Bernd Gaede, Tony Mossman
Publikováno v:
Blood. 108:1552-1552
Background and Aim: The role of IV iron supplementation during treatment with erythropoiesis-stimulating agents (ESAs) in patients with CIA is of increasing interest as a possible means of improving response. This randomized, open-label, multicenter